OSE Immuno: positive interim analysis of study data
'In this interim analysis, no safety alerts were detected. Adverse events were those classically observed in kidney transplantation, and no acute rejection was observed with FR104/VEL-101.
"This major milestone marks a key advance in the clinical development of the CD28 antagonist FR104/VEL-101 towards a Phase 2 trial", says Nicolas Poirier, CEO of the biopharmaceutical company.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction